{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/angio-oedema-anaphylaxis/background-information/prevalence/","result":{"pageContext":{"chapter":{"id":"a4358430-db1f-55c2-9d68-6ce8076813ba","slug":"prevalence","fullItemName":"Prevalence","depth":2,"htmlHeader":"<!-- begin field 60f4969c-e4f2-4b25-ba2f-37f3378acda7 --><h2>How common is it?</h2><!-- end field 60f4969c-e4f2-4b25-ba2f-37f3378acda7 -->","summary":"","htmlStringContent":"<!-- begin item e3dac265-1204-438e-8c1d-4b71b1f89f92 --><!-- begin field 159d0243-c011-4784-b474-9e3b08da1353 --><ul><li><strong>Angio-oedema is common. </strong><ul><li>It occurs with urticaria in around 40% of cases [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Marzano, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>], and about 10% of people experience only angio-oedema without urticaria [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">S&aacute;nchez-Borges, 2012</a>].</li><li>Angiotensin-converting enzyme (ACE) inhibitor-related angio-oedema occurs in about 0.7% of people taking this drug and is more common in black people than in white people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>].</li><li>Hereditary angio-oedema is rare, with estimates of prevalence ranging from 1 in 10,000 to 1 in 50,000 people. It usually presents after puberty [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Kaplan, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Cicardi, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">ASCIA, 2017</a>].</li><li>Acquired angio-oedema is even more rare, with crude estimated prevalence ranging from 1 in 100,000 to 1 in 500,000 people. It usually occurs after the fourth decade of life [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Cicardi, 2010</a>]. </li></ul></li><li><strong>The true incidence and prevalence of anaphylaxis are difficult to establish. </strong><ul><li>Based on results from a number of international epidemiological studies, the overall frequency of episodes of anaphylaxis is estimated to be between 30–950 cases per 100,000 persons per year, and the lifetime prevalence is between 50–2000 episodes per 100,000 persons (or 0.05–2.0%) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Lieberman, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Resuscitation Council (UK), 2012</a>].</li><li>This is in line with UK primary care data which indicated a lifetime age-standardized prevalence of a recorded diagnosis of anaphylaxis of 75.5 per 100,000 in 2005. Based on these data, it is estimated that about 1 in 1333 of the English population has experienced anaphylaxis at some point in their lives [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Resuscitation Council (UK), 2012</a>].</li><li>A systematic review found that the incidence rates for all-cause anaphylaxis ranged from 1.5–7.9 per 100,000 person-years, with studies from the UK showing an increase in admissions with anaphylaxis over the last two decades (based on results of 10 European studies). The data indicated that an estimated 0.3% (95% CI 0.1–0.5) of the population experience anaphylaxis at some point in their lives (prevalence data based on 3 population-based studies) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Panesar, 2013</a>].</li></ul></li></ul><!-- end field 159d0243-c011-4784-b474-9e3b08da1353 --><!-- end item e3dac265-1204-438e-8c1d-4b71b1f89f92 -->","topic":{"id":"4e83ca20-0eac-5432-adf1-cb9a0716c558","topicId":"41b219ac-b62a-42d3-9d76-7b3897b21bdd","topicName":"Angio-oedema and anaphylaxis","slug":"angio-oedema-anaphylaxis","lastRevised":"Last revised in November 2018","chapters":[{"id":"f7de7576-f193-57e1-8566-52f77c198d07","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"137d41e2-195c-5b6c-a42b-a2e7774ab4c5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2d19b26a-ca5e-5feb-8be8-12f596f24eed","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"76defb8d-d620-56bc-bf42-cc72dd02704f","slug":"changes","fullItemName":"Changes"},{"id":"0124664c-1848-504a-b629-b001f3d627e7","slug":"update","fullItemName":"Update"}]},{"id":"fd3fe5d3-198d-5e2e-afaa-1de509ee14b0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8c36d3c5-8fc2-58ba-91d9-2d00dbb17605","slug":"goals","fullItemName":"Goals"},{"id":"dbfbfeb0-8ad4-5a3d-8458-06af672eab12","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bbc732dc-6fbc-5902-a5bf-890776f1df44","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"49ccfcd1-6054-5eac-b6a2-c85eb605ecfd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4c97855a-e489-54e6-8f4b-28dbc050951e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"71eafab9-7c66-5e57-aa08-197ad09eb9e7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2c158e9f-bfe1-56ea-a1fe-97e4da83b82d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ed1b7bb1-0232-5ceb-991c-c936ac2a3086","slug":"definition","fullItemName":"Definition"},{"id":"ac67665b-2b88-5df8-9a70-cc35f96825ae","slug":"causes-trigger-factors","fullItemName":"Causes/trigger factors"},{"id":"a4358430-db1f-55c2-9d68-6ce8076813ba","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7ebee135-258e-58ce-a91e-947b8a2f9563","slug":"complications","fullItemName":"Complications"},{"id":"7c2a6ca1-0f6a-5a40-bc06-dbbbf95c57c1","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4b20303c-5905-594a-a8c6-4f85e46cf3f9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"005b06b8-18c4-569f-b1b3-3c6d1218ddf7","slug":"diagnosis-of-angio-oedema","fullItemName":"Diagnosis of angio-oedema"},{"id":"682e56cf-4c4d-5736-8db7-4cd4bfcab6e2","slug":"assessing-the-cause-of-angio-oedema","fullItemName":"Assessing the cause of angio-oedema"},{"id":"bf860a63-b9a4-5c14-bf1b-46423d3df7ad","slug":"diagnosis-of-anaphylaxis","fullItemName":"Diagnosis of anaphylaxis"},{"id":"fab5c932-e15e-5303-99e9-48f7d2e415b4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1c5f38ef-17d4-569d-ad54-b819fd953d6c","fullItemName":"Management","slug":"management","subChapters":[{"id":"654a5e70-49b7-58b4-b976-7e94c44b3074","slug":"angio-oedema-without-anaphylaxis","fullItemName":"Scenario: Angio-oedema without anaphylaxis"},{"id":"5759117d-4bde-53b6-b78d-7885ccbf431e","slug":"anaphylaxis-with-or-without-angio-oedema","fullItemName":"Scenario: Anaphylaxis with or without angio-oedema"}]},{"id":"6f94e28f-193d-587a-a11a-0a05a1be037f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b59ab8fd-de1f-555e-946a-c3a53b918da4","slug":"emergency-drug-doses","fullItemName":"Emergency drug doses"},{"id":"69e007b8-2046-5946-a7b5-de8f1bb9de9f","slug":"non-sedating-antihistamines-no-airway-involvement","fullItemName":"Non-sedating antihistamines (no airway involvement)"},{"id":"dac089ca-3b63-536d-9737-82806f78b88e","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"}]},{"id":"7ead2f48-36a4-5547-8570-4d4ab5898a73","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a7653e34-460d-5737-b0c3-264ecc26dc68","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a713ee82-3188-50ea-a2bc-a562abd97621","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7421fd02-2e34-5526-bd39-905aa772f800","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d24df800-eddc-5bf3-bea0-d556b5e01aed","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"af27ed5c-0853-5d16-91a4-5e5878ee9209","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f7640a76-8bc4-569e-8b82-717e6bd5f041","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b4778aa1-f37d-574f-8514-47ac86bf2c2e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2c158e9f-bfe1-56ea-a1fe-97e4da83b82d","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}